ImmunityBio (IBRX) Short-term Investments (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Short-term Investments data on file, last reported at $175.7 million in Q1 2026.

• Quarterly Short-term Investments rose 18770.57% year-over-year to $175.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $175.7 million (up 18770.57% YoY) and the FY2025 annual result came in at $154.5 million, up 2321.0% from the prior year.
• Short-term Investments advanced to $175.7 million in Q1 2026 per IBRX's latest filing, from $154.5 million in the prior quarter.
• Across five years, Short-term Investments topped out at $197.6 million in Q3 2025 and bottomed at $931000.0 in Q1 2025.
• The 5-year median for Short-term Investments is $16.0 million (2025), against an average of $52.9 million.
• The widest annual swing landed in 2023, when Short-term Investments plunged 98.21%; it then soared 18770.57% in 2026.
• Tracing IBRX's Short-term Investments over 5 years: stood at $2.5 million in 2022, then sank by 60.32% to $1.0 million in 2023, then surged by 532.41% to $6.4 million in 2024, then surged by 2321.0% to $154.5 million in 2025, then increased by 13.72% to $175.7 million in 2026.
• Per Business Quant, the three latest IBRX Short-term Investments figures stand at $175.7 million (Q1 2026), $154.5 million (Q4 2025), and $197.6 million (Q3 2025).

Peer Comparison